AZN discontinues AZD2820

Palatin Technologies Inc. (NYSE:PTN) said partner AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued AZD2820, a melanocortin (MC) receptor partial agonist that was in development for obesity. In June, A...